Conditions

This post was originally published on this site On Sept. 20, the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe) and the European Society of Gynaecological Oncology (ESGO) presented the first World Gynecologic Oncology Day (World GO Day). Spearheaded by ENGAGe, the initiative, set to occur annually, aims to promote collaboration among patient groups, strengthen…

This post was originally published on this site Prolaris, a genetic test developed by Myriad Genetics to help predict the aggressiveness of prostate cancer, can accurately identify prostate cancer patients with low-risk disease who may safely opt for active surveillance, a study found. Among 547 men who choose active surveillance, only two experienced tumor progression…

This post was originally published on this site A combination of ilixadencel plus Sutent (sunitinib) is showing promising efficacy in patients with kidney cancer that has spread to other organs, according to topline data from a Phase 2 trial. Ilixadencel, Immunicum‘s lead candidate for the treatment of different types of solid tumors, is a cancer…

This post was originally published on this site Fate Therapeutics has been cleared by the U.S. Food and Drug Administration (FDA) to initiate clinical studies evaluating FT596, its off-the-shelf cell-based immunotherapy designed to target multiple tumor proteins. The company plans to start testing FT596 for the treatment of B-cell lymphoma and chronic lymphocytic leukemia, either…

This post was originally published on this site Sarcoidosis patients and their partners experience a lower quality of life because of nonspecific disease-associated symptoms compared to healthy people, a new study demonstrated.  The study, titled “Quality of Life of Couples Living with Sarcoidosis,” was published in the journal Respiration. Sarcoidosis is an inflammatory disease affecting…

This post was originally published on this site Because access to prior mammograms is critical for women during all stages of breast health, Life Image is offering free membership during October — Breast Cancer Awareness Month — to its unique health management platform. At the same time, the global network for sharing clinical and imaging…

This post was originally published on this site The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended that a combination of Bavencio (avelumab) and Inlyta (axitinib) be approved for the first-line treatment of adults with advanced renal cell carcinoma, the most common form of kidney cancer.…

This post was originally published on this site CT053, a novel cell-based therapy being developed by Carsgen Therapeutics, was given priority medicines (PRIME) status by the European Medicines Agency (EMA) as a potential treatment of relapsed or refractory multiple myeloma. Early findings from a Phase 1 trial in people with heavily pre-treated disease support the therapy’s…

This post was originally published on this site Spherix announced that it has closed an exclusive option agreement to license PrAg-PAS, an anthrax-based potential therapy for ovarian cancer developed by scientists at the University of Maryland at Baltimore (UMB). The agreement gives Spherix rights to a patent application, now under consideration by the U.S. Patents Trademark…

This post was originally published on this site Xynomic Pharmaceutical‘s abexinostat has received Fast Track Designation by the U.S. Food and Drug Administration (FDA) as a fourth-line treatment for follicular lymphoma, the company announced in a press release. The decision comes after Xynomic applied for the designation at the beginning of August. The FDA grants…

This post was originally published on this site Eating mushrooms frequently — three times a week or more — may have a reduced risk of prostate cancer compared to those eating mushrooms less than once a week, a study of Japanese men found. The association holds true only for men 50 or older, according to…